CRISPR Delivery Systems| Wed. May 26, 2021 | 3:00 pm–6:00 pm CEST / 9:00 am–12:00 pm EDT | Free CMN Webinar
CRISPR Delivery Systems
Trafficking CRISPR components into cells remains a major challenge in the genome editing field. There are currently three key categories of CRISPR delivery methods – viral, chemical, and physical – each of which comprises several different vehicles. Viral delivery vehicles include adeno-associated viruses (AAVs), full-size adenoviruses (AdVs), and lentiviruses (LVs). Chemical delivery vehicles, otherwise known as nano delivery vehicles, include liposomes and lipid nanoparticles, lipoplexes and polyplexes, inorganic nanoparticles, and cell-penetrating peptides. Physical delivery vehicles include electroporation, microinjection, microfluidics, and hydrodynamic delivery.
The vehicle chosen for delivery must be compatible with several other key factors to achieve efficient and safe CRISPR editing, especially for therapeutic applications. These factors include the CRISPR cargo used, whether it be a DNA plasmid, mRNA, or a ribonucleoprotein complex, the nature of the experiment i.e. in vivo, ex vivo, or in vitro, and the target cell or organism. There has been significant recent progress in CRISPR delivery research, with improvements in older delivery vehicles and the emergence of novel delivery technologies.
In this webinar, we will describe established methods of CRISPR delivery, discuss nascent delivery techniques, and speak with experts who are working at the cutting edge of CRISPR delivery technologies for research and therapeutic purposes.
- Yizhou Dong, Associate Professor, Ohio State University, US (CMN interview)
- Christian Grøndahl, Dr. Med. Co-founder & CEO, SNIPR BIOME, DK (CMN interview)
- Yuan Ping, PhD, Principal Investigator, Zhejiang University, China (Publication)
- Anna Gutkin, PhD, Dan Peer’s Lab in Tel Aviv, Israel (CMN interview)
Sign up to the Webinar
CRISPR Delivery Systems | Wednesday May 26, 2021 | 15:00 pm–18:00 pm CEST / 9:00 am –12:00 am EDT | Free CMN Webinar
Yizhou Dong, Associate Professor, Ohio State University, US
Yizhou Dong is an Associate Professor in the Division of Pharmaceutics and Pharmacology, College of Pharmacy at The Ohio State University. He received his B.S. in pharmaceutical sciences from Peking University, Health Science Center and M.S. in organic chemistry from Shanghai Institute of Organic Chemistry. In 2009, he received his Ph.D. degree in pharmaceutical sciences from the University of North Carolina at Chapel Hill (UNC-CH) under the supervision of Professor K.-H. Lee. From 2010 to 2014, he was a postdoctoral fellow in the laboratory of Professors Robert Langer and Daniel Anderson at Harvard Medical School and Massachusetts Institute of Technology. His research focuses on the design and development of biotechnology platforms for the treatment of genetic disorders, infectious diseases, and cancers.
Dr. Dong has authored over seventy papers and patents. Several of his inventions have been licensed and are currently under development as drug candidates for clinical trials. He serves as a scientific advisory board member for Oncorus Inc. Dr. Dong is the recipient of Young Innovator in Cellular and Molecular Bioengineering from the Biomedical Engineering Society, Maximizing Investigators’ Research Award from the National Institute of General Medical Sciences (NIGMS), Ohio State Early Career Innovator of the Year, and The American Association of Pharmaceutical Scientists (AAPS) Emerging Leader Award.
Anna Gutkin, PhD, Dan Peer’s Lab in Tel Aviv, Israel
Anna Gutkin is a PhD student in Dan Peer’s Precision nanomedicine laboratory at Tel- Aviv University. She received her B.Sc. (cum laude) in the combined program for Medical and life science at Tel- Aviv University and M.Sc. in Molecular Genetics and Biochemistry (summa com laude) at Tel- Aviv University. Her Ph.D. research project focuses on harnessing genome editing nanomedicine for cancer therapy.
Her research in collaboration with Dr. Daniel Rosenblum was recently published in Science Advances and arouse great interest. In the past year, she received 7 excellence prizes for her work including the prestigious Marian-Gertner Institute for Medical Nanosystems Excellence Research award, The Smolarz Research Excellence award and the Glazer Excellence Award for outstanding graduate students.
Anna Gutkin is a PhD student in Dan Peer’s Precision nanomedicine laboratory at Tel Aviv University in Israel. She received a B.Sc. (cum laude) in the combined program for Medical and Life Science and a M.Sc. in Molecular Genetics and Biochemistry (summa com laude), both at Tel Aviv University. Her PhD research project focuses on harnessing genome editing nanomedicine for cancer therapy.
Her research in collaboration with Dr. Daniel Rosenblum was recently published in Science Advances and arose great interest. In the past year, she received 7 excellence prizes for her work including the prestigious Marian-Gertner Institute for Medical Nanosystems Excellence Research award, The Smolarz Research Excellence award and the Glazer Excellence Award for outstanding graduate students.
Christian Grøndahl, Dr. Med, DVM, PhD, MBA
Christian Grøndahl has worked in the pharma/biotech industry for +25 years in Copenhagen, Denmark and in Cambridge and London, UK.
Christian is the co-founder and CEO of SNIPR BIOME, Copenhagen, Denmark, a biotech with 40 scientific staff founded on novel and patent-protected CRISPR technology in mixed microbial communities. SNIPR BIOME focuses on human/gut microbiome modulation for immune-oncology, orphan diseases and catastrophic infectious diseases. Christian is the co-inventor of the seminal issued US CRISPR patent WO/US9701964 as well the co-inventor of 15 other issued CRISPR patents and patent applications in US and RoW.
Christian is also co-founder and Chairman of the industrial agritech FOLIUM SCIENCES Ltd., Cambridge, UK, which pioneers CRISPR-based microbiome modulators in the food, feed and agritech space. Folium currently employs 15 scientists.
Christian has a long-standing background in research, development, and corporate development roles within Denmark and the UK and has held major founding and executive roles in companies within the gene therapy, immuno-oncology, metabolism and cancer fields.
He is the co-inventor of +30 patents and patent applications with Novo Nordisk A/S, Zealand A/S, Kymab Ltd., Syncona Limited, Quadrucept Bio Ltd., SNIPR Technologies Ltd. and SNIPR Biome Aps.
A few sponsor packages will be available for this CMN Webinar.
Please contact us for more information: firstname.lastname@example.org
CMN Articles - CRISPR Delivery